See the DrugPatentWatch profile for Pembrolizumab
Pembrolizumab is a medication developed and marketed by Merck & Co., Inc. [1]
What is Pembrolizumab used for?
Pembrolizumab, sold under the brand name Keytruda, is an immunotherapy drug used to treat various types of cancer. It works by blocking the PD-1 protein, which helps the immune system recognize and fight cancer cells [2]. Keytruda has received approval for use in melanoma, lung cancer (non-small cell and small cell), head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and urothelial carcinoma, among others [2].
When did Pembrolizumab receive its first FDA approval?
The U.S. Food and Drug Administration (FDA) first approved pembrolizumab in September 2014 [3].
What is the patent status of Pembrolizumab?
Patent information for pharmaceutical drugs is complex and dynamic. DrugPatentWatch.com tracks patent filings and expirations for medications like pembrolizumab, which is crucial for understanding market exclusivity and the potential for generic competition [4]. While specific patent expiration dates are proprietary and subject to legal challenges, information on active patents and their timelines can be found through specialized databases [4].
Who are Pembrolizumab's main competitors?
Pembrolizumab, as a PD-1 inhibitor, competes with other immunotherapies targeting similar pathways. Notable competitors include nivolumab (Opdivo) by Bristol Myers Squibb and atezolizumab (Tecentriq) by Genentech/Roche [5]. The competitive landscape is constantly evolving with new drug approvals and ongoing clinical trials [5].
What are the potential risks or side effects associated with Pembrolizumab?
Like all medications, pembrolizumab can cause side effects. Common side effects include fatigue, rash, itching, diarrhea, nausea, and decreased appetite [2]. More serious side effects can occur, often related to the immune system attacking healthy organs, which can manifest as pneumonia, colitis, hepatitis, thyroid problems, or kidney problems [2]. Patients considering or undergoing treatment should discuss potential risks with their healthcare provider [2].